摘要
目的观察原发性高血压病患者长期服用小剂量氢氯噻嗪的降压疗效。方法116例轻、中度高血压病患者服用氢氯噻嗪12.5mg,2次/d,每月发放一次药物并测量血压,观察1年,比较服药12周及1年的降压疗效及生化指标的变化。结果①观察结束时资料完整的观察对象为115例,治疗后12周的收缩压、舒张压、平均动脉压下降值分别为(6.12±16.17)mmHg、(2.92±10.33)mmHg、(3.97±10.68)mmHg。治疗1年的收缩压、舒张压、平均动脉压下降值分别为(10.56±17.38)mmHg、(8.45±11.16)mm-Hg、(9.27±10.78)mmHg。1年时血压下降值高于12周时血压下降值,差异有统计学意义(P<0.05)。治疗12周时的降压达标率为20.6%,治疗1年时降压达标率为37.1%,差异有统计学意义(P<0.05)。②观察结束时未发现有症状的低钾血症,但血尿酸值明显增加,与基线值比较差异有统计学意义(P<0.05)。结论长期服用小剂量氢氯噻嗪可有效降低轻、中度原发性高血压患者的血压,对电解质、糖、脂代谢无明显不良影响。
Objective To investigate the chronic efficacy of low - dose hydrochlorothiazide（HCTZ） in patients with mild - to- moderate hypertension. Methods After a 2 - weeks placebo run- in period, 116 patients with mild or moderate hypertension were recruited and received HCTZ（12.5mg twice daily） therapy for 1 year. Patient compliance and blood pressure were monitored and serum BUN, Cr, glucose, electrolytes, and lipids were measured before, 12weeks and 1 year after treatment. Results （1）Reduction of SBP, DBP and MAP were more significant at 1 year（10. 56 ± 7. 38）mmHg, （8.45 ±11.16）mmHg, （9.27 ± 10.78）mmHg than those at 12 weeks post therapy（6.12± 16.15）mmHg, （2.92± 10.33）mmHg, （3.97 ± 0.68） mmHg （P〈0.05）. Blood pressure were reduced to normal in 37.1% patients at 1 year and in 20.6% patients in 12 weeks（P〈0.05）. （2）No patient developed diabetes mellitus or hypokalemia during therapy while the serum uric acid at 1 year post therapy was significantly higher than that at before therapy（P〈0.05）. Conclusion The study indicates that low dose HCTZ is an effective and safe antihypertensive agent for patients with mild- to - moderate hypertension and uric acid changes during therapy need to be monitored.
出处
《中国煤炭工业医学杂志》
2008年第6期791-794,共4页
Chinese Journal of Coal Industry Medicine
关键词
高血压
氢氯噻嗪
生化指标
hypertension
hydrochlorothiazide
biochemical value
